HIGHTIDE-B: The world's first anti-inflammatory metabolic regulator HTD1801 has completed Phase III clinical research for Type 2 diabetes, demonstrating sustained comprehensive benefits and safety advantages over 52 weeks
I'm PortAI, I can summarize articles.
HIGHTIDE-B announced that its anti-inflammatory metabolic regulator HTD1801 has successfully completed Phase III clinical trials in patients with type 2 diabetes, demonstrating efficacy and safety advantages over 52 weeks. The study results show that HTD1801 is effective in reducing blood lipids and inflammatory markers, and long-term treatment is safe. The company plans to submit a new drug application for HTD1801 to the National Medical Products Administration within this year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments